Nov 12, 2025 7:00 am EST Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
Nov 6, 2025 7:00 am EST Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
Nov 3, 2025 8:00 am EST Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
Oct 14, 2025 8:00 am EDT Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
Oct 2, 2025 8:00 am EDT Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
Sep 30, 2025 7:00 am EDT Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Sep 4, 2025 8:00 am EDT Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions